Article: Cyclacel Conserving Resources - Analyst Blog

Cyclacel Conserving Resources - Analyst Blog


CYCC: Focus on Key Programs to Conserve Resources

Cyclacel Pharmaceuticals, Inc. ( CYCC ) is a clinical-stage company dedicated to the discovery, development, and commercialization of small molecule cell cycle inhibitors for the treatment of cancers and other serious disorders. The company's expertise lies in the area of Cell Cycle Inhibition which is a mechanism-targeted approach for the treatment of cancer and other serious proliferative diseases.

Cyclacel aims to develop novel, cell-cycle-based mechanism-targeted cancer therapies that will stop the growth of cancer cells and will limit the damage caused to normal cells. The company ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!